📣 VC round data is live. Check it out!

SI-BONE Valuation Multiples

Discover revenue and EBITDA valuation multiples for SI-BONE and similar public comparables like BrainsWay, Lumibird, CeriBell, SD Biosensor and more.

SI-BONE Overview

About SI-BONE

SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.


Founded

2008

HQ

United States

Employees

559

Financials (LTM)

Revenue: $212M
EBITDA: $10M

EV

$527M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

SI-BONE Financials

SI-BONE reported last 12-month revenue of $212M and EBITDA of $10M.

In the same LTM period, SI-BONE generated $169M in gross profit, $10M in EBITDA, and had net loss of ($19M).

Revenue (LTM)


SI-BONE P&L

In the most recent fiscal year, SI-BONE reported revenue of $201M and EBITDA of $9M.

SI-BONE is unprofitable as of last fiscal year, with gross margin of 80%, EBITDA margin of 4%, and net margin of (9%).

See analyst estimates for SI-BONE
LTMLast FY202320242025202620272028
Revenue$212M$201M$139M$167M$201M
Gross Profit$169M$160M$109M$132M$160M
Gross Margin79%80%79%79%80%
EBITDA$10M$9M($34M)($23M)($11M)
EBITDA Margin5%4%(25%)(14%)(5%)
EBIT Margin(10%)(11%)(34%)(21%)(11%)
Net Profit($19M)($19M)($43M)($31M)($19M)
Net Margin(9%)(9%)(31%)(18%)(9%)

Financial data powered by Morningstar, Inc.

SI-BONE Stock Performance

SI-BONE has current market cap of $628M, and enterprise value of $527M.

Market Cap Evolution


SI-BONE's stock price is $14.17.

SI-BONE share price increased by 14.4% in the last 30 days, and decreased by 25.0% in the last year.

SI-BONE has an EPS (earnings per share) of $-0.43.

See more trading valuation data for SI-BONE
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$527M$628M-2.9%14.4%-8.7%-25.0%$-0.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

SI-BONE Valuation Multiples

SI-BONE trades at 2.5x EV/Revenue multiple, and 52.4x EV/EBITDA.

See NTM and 2027E valuation multiples for SI-BONE

EV / Revenue (LTM)


SI-BONE Financial Valuation Multiples

As of May 16, 2026, SI-BONE has market cap of $628M and EV of $527M.

SI-BONE has a P/E ratio of (32.8x).

LTMLast FY202320242025202620272028
EV/Revenue2.5x2.6x3.8x3.2x2.6x
EV/EBITDA52.4x59.0x(15.3x)(22.8x)(50.1x)
EV/EBIT(23.7x)(23.6x)(11.2x)(14.9x)(23.6x)
EV/Gross Profit3.1x3.3x4.8x4.0x3.3x
P/E(32.8x)(33.2x)(14.5x)(20.3x)(33.2x)
EV/FCF(57.9x)(19.9x)(23.0x)(57.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified SI-BONE Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

SI-BONE Margins & Growth Rates

SI-BONE grew revenue by 15% and EBITDA by 34% in the last fiscal year.

In the most recent fiscal year, SI-BONE reported gross margin of 80%, EBITDA margin of 4%, and net margin of (9%).

See estimated margins and future growth rates for SI-BONE

SI-BONE Margins

Last FY202420252026202720282029
Gross Margin80%79%80%79%
EBITDA Margin4%(14%)(5%)5%
EBIT Margin(11%)(21%)(11%)(9%)
Net Margin(9%)(18%)(9%)(8%)
FCF Margin(5%)(14%)(5%)(3%)

SI-BONE Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth15%20%20%15%
Gross Profit Growth15%21%21%15%
EBITDA Growth34%(33%)(55%)(214%)
EBIT Growth(2%)(25%)(37%)(2%)
Net Profit Growth4%(29%)(39%)4%
FCF Growth(34%)(14%)(60%)(34%)

Data powered by FactSet, Inc. and Morningstar, Inc.

SI-BONE Operational KPIs

SI-BONE's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

SI-BONE's Rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

SI-BONE's Rule of X is 43% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for SI-BONE
LTMLast FY202320242025202620272028
Rule of 4020%20%
Bessemer Rule of X43%43%
Revenue per Employee$0.4M
Opex per Employee$0.3M
S&M Expenses to Revenue62%62%79%70%62%
G&A Expenses to Revenue20%20%22%20%20%
R&D Expenses to Revenue9%9%11%10%9%
Opex to Revenue91%113%100%91%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

SI-BONE Competitors

SI-BONE competitors include BrainsWay, Lumibird, CeriBell, SD Biosensor, Synektik, Polynovo, Sunmax Biotechnology, Japan Lifeline, QuidelOrtho and Anteris Technologies US.

Most SI-BONE public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
BrainsWay10.9x9.9x58.2x62.5x
Lumibird2.8x2.7x14.1x13.2x
CeriBell5.6x5.1x(10.0x)(9.4x)
SD Biosensor1.2x(1.3x)
Synektik2.9x2.6x11.7x10.2x
Polynovo6.4x5.6x77.9x72.1x
Sunmax Biotechnology9.9x17.9x
Japan Lifeline1.4x1.3x5.8x5.6x

This data is available for Pro users. Sign up to see all SI-BONE competitors and their valuation data.

Start Free Trial

SI-BONE Funding History

Before going public, SI-BONE raised $80M in total equity funding, across 3 rounds.


SI-BONE Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-16Undisclosed stageArboretum Ventures; Employee Stock Option Fund; Montreux Equity Partners; OrbiMed; Redline Capital; Skyline Ventures$26M
May-15Undisclosed stageMontreux Equity Partners; OrbiMed; Redline Capital; Skyline Ventures$21MSI-BONE is a medical device company based in San Jose, California, specializing in minimally invasive surgical solutions for sacroiliac (SI) joint dysfunction using its iFuse Implant System to fuse the SI joint and alleviate lower back pain. The company develops and commercializes implantable devices like iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite for applications in spinal deformity, degeneration, and pelvic trauma. In May 2015, SI-BONE raised approximately $21 million in a funding round led by new investor Redline Capital Management, with participation from existing backers including Montreux Equity Partners, OrbiMed, and Skyline Ventures, as reported in news from May 28, 2015; proceeds were intended for general corporate purposes including appointing a new CFO, Laura Francis. A prior $33 million growth capital round closed in April 2014 with investments from OrbiMed, Novo A/S, Skyline Ventures, and Montreux Equity Partners to expand U.S. sales, R&D, international regulatory approvals, and clinical studies like SIFI.
Apr-14Undisclosed stageMontreux Equity Partners; Novo Holdings; OrbiMed; Skyline Ventures$33MSI-BONE Inc. is a medical device company focused on treating the sacroiliac (SI) joint, an under-served area in orthopedics. The company was founded to address diagnosis and treatment gaps in this specific orthopedic market. SI-BONE completed an initial public offering in 2018. As of 2024, the company had annual revenue of $167.18M with 20.37% growth year-over-year, and trailing twelve-month revenue of $185.26M as of June 30, 2025, representing 22.93% growth. The company currently employs 349 people and has a market capitalization of approximately $605.70M.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About SI-BONE

When was SI-BONE founded?SI-BONE was founded in 2008.
Where is SI-BONE headquartered?SI-BONE is headquartered in United States.
How many employees does SI-BONE have?As of today, SI-BONE has over 559 employees.
Who is the CEO of SI-BONE?SI-BONE's CEO is Laura A. Francis.
Is SI-BONE publicly listed?Yes, SI-BONE is a public company listed on Nasdaq.
What is the stock symbol of SI-BONE?SI-BONE trades under SIBN ticker.
When did SI-BONE go public?SI-BONE went public in 2018.
Who are competitors of SI-BONE?SI-BONE main competitors include BrainsWay, Lumibird, CeriBell, SD Biosensor, Synektik, Polynovo, Sunmax Biotechnology, Japan Lifeline, QuidelOrtho, Anteris Technologies US.
What is the current market cap of SI-BONE?SI-BONE's current market cap is $628M.
What is the current revenue of SI-BONE?SI-BONE's last 12 months revenue is $212M.
What is the current revenue growth of SI-BONE?SI-BONE revenue growth (NTM/LTM) is 15%.
What is the current EV/Revenue multiple of SI-BONE?Current revenue multiple of SI-BONE is 2.5x.
Is SI-BONE profitable?Yes, SI-BONE is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of SI-BONE?SI-BONE's last 12 months EBITDA is $10M.
What is SI-BONE's EBITDA margin?SI-BONE's last 12 months EBITDA margin is 5%.
What is the current EV/EBITDA multiple of SI-BONE?Current EBITDA multiple of SI-BONE is 52.4x.
How many companies SI-BONE has acquired to date?SI-BONE hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies SI-BONE has invested to date?SI-BONE hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to SI-BONE

Lists including SI-BONE

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial